Treatment Outcome In Schizophrenia Research Articles

Heart rate variability in schizophrenic patients: Effect of clozapine

The outcome of treatment in schizophrenia is best considered as a multidimensional construct. This report lists thirteen categories of outcome measures that have been studied in schizophrenia research, among the most important of which are psychopathology, cognitive function, interpersonal social function, quality of life, extrapyramidal function, the suicide tendeccy and the need for hospitalisation. Clozapine is effective in achieving improved outcome in all these measures in a high percentage of neuroleptic-resistant patients. Ninety-two of 180 (51.1%) clozapine-treated neuroleptic-resistant patients achieved a decrease of 20% in Brief Psychiatric Rating Scale total scores at six weeks using the 0–6 scaling system. Cognitive function contributes importantly to overall function for schizophrenia. Clozapine has been shown to improve some types of cognition in schizophrenia, especially semantic memory and some tests of executive function. Clozapine has also been shown to decrease the incidence of suicide and hospitalisation. The task of deciding which therapies to use in schizophrenia should encompass the spectrum of benefits of each therapy, their risks and costs, in relation to all alternatives.

Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods

Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods

Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine

The outcome of treatment in schizophrenia is best considered as a multidimensional construct. This report lists thirteen categories of outcome measures that have been studied in schizophrenia research, among the most important of which are psychopathology, cognitive function, interpersonal social function, quality of life, extrapyramidal function, the suicide tendeccy and the need for hospitalisation. Clozapine is effective in achieving improved outcome in all these measures in a high percentage of neuroleptic-resistant patients. Ninety-two of 180 (51.1%) clozapine-treated neuroleptic-resistant patients achieved a decrease of 20% in Brief Psychiatric Rating Scale total scores at six weeks using the 0-6 scaling system. Cognitive function contributes importantly to overall function for schizophrenia. Clozapine has been shown to improve some types of cognition in schizophrenia, especially semantic memory and some tests of executive function. Clozapine has also been shown to decrease the incidence of suicide and hospitalisation. The task of deciding which therapies to use in schizophrenia should encompass the spectrum of benefits of each therapy, their risks and costs, in relation to all alternatives.

Treatment outcomes in schizophrenia: implications for practice, policy, and research.

Outcomes research on treatments for schizophrenia has identified a number of efficacious interventions. The degree to which such scientific knowledge influences the care delivered in everyday practice depends on a large number of patient, practitioner, service system, and other social factors. The current atmosphere for change in the health care delivery system poses both risks and opportunities to improve care for persons with this disorder. Scientific knowledge about treatment outcomes must inform this rapid evolution of practice, policy, and research to ensure that effective treatments are preserved and available for all who need them and that new treatments continue to be developed, evaluated, and disseminated.

Maximizing schizophrenia treatment outcomes: A model for reintegration.

Maximizing schizophrenia treatment outcomes: A model for reintegration.

Biological variables in predicting the outcome of psychological treatment in schizophrenia

Biological variables in predicting the outcome of psychological treatment in schizophrenia

Neuropsychological functioning and treatment outcome in schizophrenia : Robert S. Goldman, Rajiv Tandon, Bradley N. Axelrod, Saulo C.M. Ribeiro, Katherine Craig The University of Michigan, Ann Arbor, MI 48109-0120

Neuropsychological functioning and treatment outcome in schizophrenia : Robert S. Goldman, Rajiv Tandon, Bradley N. Axelrod, Saulo C.M. Ribeiro, Katherine Craig The University of Michigan, Ann Arbor, MI 48109-0120

The Predictive Value of Psychopathological Subclassifications for the Neuroleptic Treatment Outcome in Schizophrenia

In the group of 58 schizophrenic patients who fulfilled the DSM-III-R criteria for schizophrenia, various subgroups have been identified according to the DSM-III-R subdivision of schizophrenic types, the DCR classification of systematic, nonsystematic schizophrenia and cycloid psychosis, as well as positive/negative symptoms of schizophrenia. All patients underwent therapy with one neuroleptic from four different neuroleptic groups. Some significant differences between the subgroups in respect to sociodemographic data were found. The DCR subdivision of patients revealed the majority of meaningful data regarding the predictive validity of psychopathology for the outcome of the neuroleptic treatment.

Blink rate response to haloperidol as possible predictor of therapeutic outcome

The purpose of our study was to further test the observed relationship between blink rate change and clinical improvement under neuroleptics, and to evaluate the predictive value of blink rate change to test doses of haloperidol for the short-term outcome of treatment in schizophrenia

Therapist experience, general clinical ability, and treatment outcome in schizophrenia.

Therapist experience, general clinical ability, and treatment outcome in schizophrenia.

Therapist experience, general clinical ability, and treatment outcome in schizophrenia.

Therapist experience, general clinical ability, and treatment outcome in schizophrenia.

A REVIEW OF THE DRASTIC SHOCK THERAPIES IN THE TREATMENT OF THE PSYCHOSES

Article1 March 1943A REVIEW OF THE DRASTIC SHOCK THERAPIES IN THE TREATMENT OF THE PSYCHOSESFRANKLIN G. EBAUGH, M.D., F.A.C.P.FRANKLIN G. EBAUGH, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-18-3-279 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring the past decade we have seen progressive changes in medical education and practice which have led to closer relationships between psychiatry and general medicine. We now accept psychiatry as that part of medicine which deals with the pathology and therapy of the person, instead of thinking of it as an isolated specialty dealing with advanced psychopathological disorders usually already admitted to institutions for treatment in the later stages of development when therapy is most difficult, more prolonged and less effective. Through this breakdown of the isolation of psychiatric medicine from basic general medicine we are now beginning to see...Bibliography1. JESSNERRYAN LVG: Shock treatment in psychiatry, 1941, Grune and Stratton, New York. Google Scholar2. U. S. Public Health Service Shock Survey, 1941. Google Scholar3. FROSTIG JP: Clinical observations in insulin treatment in schizophrenia: preliminary report, Am. Jr. Psychiat., 1940, xcvi, 1167-1190. CrossrefGoogle Scholar4. BRILLBINZILEY HRF: Involuntary eye movements—a criterion of depth of stages of insulin coma, Am. Jr. Psychiat., 1941, xcvi, 177-181. Google Scholar5. KATZENELBOGEN S: Pharmacological shock therapy, Chapter LI, Blumer's System for Practice of Medicine. Google Scholar6. ROSSMALZBERG JRB: A review of the results of the pharmacological shock therapy and the metrazol convulsive therapy in New York state, Am. Jr. Psychiat., 1939, xcvi, 297-316. CrossrefGoogle Scholar7. ROSSROSSMANCLINESCHWOERNMALZBERG JRJMWBCJB: A two year follow up study from the New York state hospitals with some recommendations for the future, Am. Jr. Psychiat., 1941, xcvii, 1007-1023. CrossrefGoogle Scholar8. CHENEYCLOW COHE: Prognostic factors in insulin shock therapy, Am. Jr. Psychiat., 1941, xcvii, 1029-1039. CrossrefGoogle Scholar9. RYMERBENJAMINEBAUGH CAJDFG: The hypoglycemic treatment of schizophrenia. A preliminary report, with particular reference to the qualitative study of remissions, Jr. Am. Med. Assoc., 1937, cix, 1249-1251. CrossrefGoogle Scholar10. PIOTROWSKI Z: A simple experimental device for prediction of the outcome of insulin treatment in schizophrenia, Psychiat. Quart., 1940, xiv, 267-273. CrossrefGoogle Scholar11. BENNETT AE: Curare: A preventive of traumatic complications in convulsive shock therapy, Am. Jr. Psychiat., 1941, xcvii, 1040-1060. CrossrefGoogle Scholar12. WHITEHEADNEUBUERGERRUTLEDGESILCOTT RWKTEKWL: Pharmacologic and pathologic effects of repeated convulsant doses of metrazol, Am. Jr. Med. Sci., 1940, cxcix, 352-359. CrossrefGoogle Scholar13. CERLETTIBINI VL: L'elettroshock, Arch. gen. di neurol. e. psichiat., 1938, xix, 266-268. Google Scholar14. WHITEHEADNEUBUERGERRUTLEDGEEBAUGH RWKTEKFG: Pathologic changes in brains of dogs given repeated electric shocks, to be published in Am. Jr. Med. Sci. Google Scholar15. U. S. Public Health Service Shock Therapy. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Denver, Colorado*Morning lecture before the American College of Physicians meeting, St. Paul, Minnesota, April 24, 1942.From the University of Colorado School of Medicine and Colorado Psychopathic Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUndoing Descartes: integrating diabetes care for those with mental illnessBibliographyEmprêgo do curare em convulsoterapiaChapter VII: Methods, Technics, and Instruments of Mental Hygiene Diagnosis and Therapy 1 March 1943Volume 18, Issue 3Page: 279-296KeywordsHospital medicineMedical educationPsychosesShock Issue Published: 1 March 1943 PDF downloadLoading ...